# Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Source: https://onco.cc/trials/nct07804186/  
OnCo record `nct07804186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Darovasertib in uveal melanoma, now recruiting.

## Summary

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma is a phase 3 interventional study registered as NCT07804186, led by IDEAYA Biosciences, and recruiting on the registry. Official title: A Randomised, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma. Planned enrolment is 450 participants (estimated). The study started in 2026-09 and primary completion is expected in 2034-03. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07804186
- Phase: 3
- Setting: A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Sponsor: IDEAYA Biosciences
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT07804186: https://clinicaltrials.gov/study/NCT07804186

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Darovasertib](https://onco.cc/drugs/darovasertib/)
- companies: [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07804186.json